IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy.
IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy; Università Piemonte Orientale, Novara, Italy.
Curr Opin Pharmacol. 2017 Aug;35:57-65. doi: 10.1016/j.coph.2017.05.007. Epub 2017 Jun 12.
Cells of the innate immunity infiltrating tumour tissues promote, rather than halt, cancer cell proliferation and distant spreading. Tumour-Associated Macrophages (TAMs) are abundantly present in the tumour milieu and here trigger and perpetrate a state of chronic inflammation which ultimately supports disease development and contributes to an immune-suppressive environment. Therapeutic strategies to limit inflammatory cells and their products have been successful in pre-clinical tumour models. Early clinical trials with specific cytokine and chemokine inhibitors, or with strategies designed to target TAMs, are on their way in different solid malignancies. Partial clinical responses and stabilization of diseases were observed in some patients, in the absence of significant toxicity. These encouraging results open new perspectives of combination treatments aimed at reducing cancer-promoting inflammation to maximize the anti-tumour efficacy.
浸润肿瘤组织的固有免疫细胞促进而非阻止癌细胞增殖和远处扩散。肿瘤相关巨噬细胞（TAMs）在肿瘤微环境中大量存在，并引发和维持慢性炎症状态，最终支持疾病发展，并有助于免疫抑制环境。限制炎症细胞及其产物的治疗策略在临床前肿瘤模型中已取得成功。针对特定细胞因子和趋化因子抑制剂的早期临床试验，或针对 TAMs 的靶向策略，正在不同的实体恶性肿瘤中进行。在一些患者中观察到部分临床反应和疾病稳定，而没有明显的毒性。这些令人鼓舞的结果为旨在减少促进癌症的炎症以最大程度提高抗肿瘤疗效的联合治疗开辟了新的前景。
